Peptide Therapeutics in Metabolic Disorders Market By Product Type (GLP-1 Receptor Agonists, Insulin and Insulin Analogs, Amylin Analogs), By Application (Type 1 Diabetes, Type 2 Diabetes, Obesity, Dyslipidemia), By End-User (Hospitals & Clinics, Diabetes Care Centers, Specialty Pharmacies), By Distribution Channel (Direct Sales, Distributors, Online Retailers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Peptide Therapeutics in Metabolic Disorders Market was valued at USD 1.9 billion in 2024-e and will surpass USD 3.1 billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

Peptide therapeutics play a vital role in the treatment of metabolic disorders, particularly in managing conditions like diabetes and obesity. The market for peptide-based therapies in metabolic disorders is growing as they offer highly targeted and effective treatment options for patients. These therapeutics include drugs that utilize peptide hormones or their analogs, such as GLP-1 receptor agonists, insulin, and amylin analogs. Peptide therapeutics provide significant advantages, such as improving insulin sensitivity, regulating blood glucose levels, and assisting in weight management. The increased prevalence of diabetes and obesity globally is a major driver for the expansion of this market.

The market for peptide therapeutics in metabolic disorders is seeing strong growth due to the rising incidence of type 1 and type 2 diabetes, as well as the increasing focus on obesity and related metabolic complications. Technological advancements in peptide drug formulations are also contributing to better outcomes and patient adherence. Moreover, the shift toward biologics and personalized treatments is pushing the demand for these innovative therapeutics.

GLP-1 Receptor Agonists Lead Product Type Segment

Among the various peptide-based therapies, GLP-1 receptor agonists are the leading product type in the treatment of metabolic disorders, especially for type 2 diabetes and obesity management. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone involved in glucose metabolism, and its synthetic analogs have proven to be highly effective in controlling blood sugar levels. GLP-1 receptor agonists not only regulate glucose but also promote weight loss by reducing appetite and slowing gastric emptying.

The increasing adoption of GLP-1 receptor agonists is attributed to their dual benefits in managing both diabetes and obesity. As more patients with type 2 diabetes also suffer from obesity, the use of GLP-1 receptor agonists is expected to rise. Additionally, these drugs are often prescribed for patients who have not achieved adequate control over their blood glucose levels with other diabetes medications, further propelling their demand.

Type 2 Diabetes and Obesity Dominate Application Segment

Type 2 diabetes is the dominant application for peptide therapeutics, as it is one of the most common metabolic disorders worldwide. Characterized by insulin resistance and high blood glucose levels, type 2 diabetes requires effective management strategies to avoid complications such as cardiovascular diseases, kidney failure, and neuropathy. Peptide-based therapies, including GLP-1 receptor agonists and insulin analogs, are becoming increasingly popular for managing blood glucose levels and improving insulin sensitivity.

Obesity, another critical application segment, is closely linked to type 2 diabetes and other metabolic diseases. As the prevalence of obesity rises globally, the demand for peptide-based therapeutics that promote weight loss, such as GLP-1 receptor agonists, is also expected to grow. These treatments are often used alongside lifestyle interventions and other medications to help patients lose weight and manage obesity-related conditions.

Hospitals & Clinics Account for Largest End-User Segment

The hospitals and clinics segment is the largest end-user category for peptide therapeutics in metabolic disorders. Hospitals and clinics provide the necessary infrastructure and medical expertise to administer these therapies effectively, especially in cases requiring specialized care for type 1 and type 2 diabetes, obesity, and other metabolic disorders. These healthcare settings also play a significant role in educating patients about the benefits and proper use of peptide-based medications.

Additionally, diabetes care centers are key players in the distribution of peptide therapeutics. These centers specialize in providing comprehensive care to individuals with diabetes, including monitoring glucose levels, adjusting medications, and managing complications. As the focus on diabetes care intensifies, the demand for peptide therapeutics in such centers is expected to grow.

Direct Sales Lead Distribution Channel

Direct sales remain the dominant distribution channel in the peptide therapeutics market for metabolic disorders. This distribution method allows manufacturers and pharmaceutical companies to establish direct relationships with healthcare providers, ensuring that medications are available when needed and that patients receive adequate support for their treatment plans. Direct sales also facilitate quicker product delivery and closer monitoring of usage, especially for injectable peptide-based therapies.

In addition to direct sales, distributors and online retailers contribute to the widespread availability of these therapies, particularly in regions outside of major metropolitan areas or in countries with emerging healthcare markets. Online sales have also seen a significant increase, driven by the convenience and accessibility they offer to patients and healthcare providers.

North America Dominates the Market

North America holds the largest share of the peptide therapeutics market for metabolic disorders. The high prevalence of diabetes and obesity, coupled with advanced healthcare systems and infrastructure, contributes to the growth of this market in the region. The United States, in particular, represents a significant portion of the market due to the high rates of type 2 diabetes, obesity, and associated conditions.

The regulatory environment in North America, particularly the U.S. Food and Drug Administration (FDA) approval process, ensures that only safe and effective peptide-based drugs are available in the market. This regulatory assurance, combined with widespread healthcare access, supports the growth of the peptide therapeutics market in North America.

Competitive Landscape

The peptide therapeutics market for metabolic disorders is highly competitive, with major pharmaceutical companies developing new and improved formulations of GLP-1 receptor agonists, insulin analogs, and other peptide-based treatments. Key players in this market are focused on expanding their product portfolios, improving drug delivery systems, and enhancing the efficacy of existing treatments.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers is increasing, as these partnerships help to accelerate the development of innovative treatments for metabolic disorders. Additionally, the growing trend toward personalized medicine, where therapies are tailored to individual patient needs, is expected to drive further growth in the peptide therapeutics market.

List of Leading Companies:

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Merck & Co., Inc.
• Boehringer Ingelheim
• Amgen Inc.
• Pfizer Inc.
• GlaxoSmithKline
• Roche
• Biocon Ltd.
• Zealand Pharma
• Medtronic
• AbbVie Inc.
• Intarcia Therapeutics

Recent Developments:

• In December 2024, Novo Nordisk launched a new GLP-1 receptor agonist for Type 2 diabetes management.
• In November 2024, Eli Lilly and Company announced the approval of a novel insulin analog for Type 1 diabetes.
• In October 2024, Sanofi introduced a new amylin analog therapy for obesity treatment.
• In September 2024, Merck & Co., Inc. expanded its portfolio of peptide-based therapeutics for metabolic disorders.
• In August 2024, AstraZeneca partnered with Boehringer Ingelheim to co-develop a peptide-based treatment for dyslipidemia.

Report Scope: